As part of the annual formulary development and management process, the next scheduled update of the 5-Tier direct/exchange formulary available to all direct pay/direct pay exchange members is scheduled for 1 de enero de 2020. All current members impacted by changes will receive individual notification no later than 1 de diciembre de 2019.

The most significant change in coverage involves a change in the preferred growth hormone to Norditropin. All existing utilization of alternative growth hormone products will require transition to Norditropin. Transition assistance will be supported through our specialty pharmacy vendor and PCMH pharmacists. Access through the specialty pharmacy network will continue to be supported.